Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Addiction Medicine
Company licenses oral drug to treat impulse control disorder
December 12th, 2004
Somaxon Pharmaceuticals, Inc. has licensed the North American rights to oral nalmefene hydrochloride from Biotie Therapies Corp. for the treatment of impulse control disorders. Nalmefene is a specific and selective opioid receptor antagonist. Pathways involving opioid receptors trigger addictive habits such as pathological gambling. Opioid receptor antagonists may prevent neurochemical reward and reinforcement, leading to a reduction in craving. Somaxon entered into an option agreement with Biotie in July 2004 pending the outcome of an end of phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the results of the...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
